世界中医药

作者	单位
冯汝丽1，曲文白1，曲信彦1，于林童1，毛天诗1，万洁2，逯金金2，李岩2，贾文浩3，林谦4	1 北京中医药大学，北京，100029； 2 北京中医药大学东方医院，北京，100078； 3 北京中医药大学第三附属医院，北京，100029； 4 北京中医药大学东直门医院，北京，100700

摘要点击次数: 311

全文下载次数: 0

中文摘要:

目的：评价口服中药治疗稳定型心绞痛的疗效及安全性。方法：计算机检索国家知识基础设施数据库（简称中国知网，China National Knowledge Infrastructure，CNKI）、中文科技期刊数据库（简称维普资讯，Chinese Citation Database，CCD）、中国学术期刊数据库（简称万方数据库，China Science Periodical Database，CSPD），PubMed，EMBASE，Cochrane lib，Google及Web of Science数据库，检索时间为建库至2019年11月1日。筛选文献、提取资料、评价偏倚风险并交叉核对后，采用Review Manager 5.3及Stata SE 12软件进行Meta分析。结果：最终纳入符合标准的随机对照试验（RCT）32篇，共34组，2 746例患者，Meta分析结果显示口服中药在改善心绞痛症状（OR=3.68，95%CI为2.97~4.57，P<0.000 01），减少心绞痛发作次数（SMD=-0.61，95%CI为-0.82~-0.39，P<0.000 01），缩短心绞痛发作时间（SMD=-0.78，95%CI为-1.16~-0.41，P<0.000 1），提高运动平板代谢当量（SMD=0.77，95%CI为0.39~1.15，P<0.000 1），改善心电图（OR=2.31，95%CI为1.88~2.82，P<0.000 01），提高硝酸甘油停减率（OR=2.42，95%CI为1.81~3.22，P<0.000 01），减少硝酸甘油用量（SMD=-0.60，95%CI为-0.96，-0.24，P＝0.001）方面均优于对照组，且不良事件较少（OR=0.49，95%CI为0.27~0.89，P＝0.02）。结论：口服中药治疗稳定型心绞痛疗效及安全性较好。

English Summary:

To evaluate the efficacy and safety of oral Chinese medicine in the treatment of stable angina pectoris.Methods:Electronic databases including CNKI,VIP,Wangfang,PubMed,EMBASE,Cochrane lib,Google and Web of Science were retrieved,the retrieval time was from the establishment of databases to November 1,2019.Reviewers screened out the literature,extracted information,evaluated risk of bias and cross check.Review Manager 5.3 and Stata SE 12 softwares were used for Meta-analysis.Results:A total of 32 studies involving 2746 patients were included,with a total of 34 groups.The results showed that the improvement of angina symptom by Chinese medicine［OR=3.68,95%CI(2.97~4.57）,P<0.000 01］,number of angina attacks［SMD=-0.61,95%CI(-0.82~-0.39),P<0.000 01］,time of angina attacks［SMD=-0.78,95%CI(-1.16~-0.41),P<0.000 1］,treadmill exercise test of metablic equivalent［SMD=0.77,95%CI(0.39~1.15),P<0.000 1］,improving electrocardiogram ［OR=2.31,95%CI(1.88~2.82)，P<0.000 01］,improving nitroglycerin deactivation rate ［OR=2.42，95%CI(1.81~3.22),P<0.000 01］,and reducing nitroglycerin consumption［SMD=-0.60,95%CI(-0.96~-0.24)，P=0.001］ were better than control groups.Fewer adverse events happened in the treatment group ［OR=0.49,95%CI(0.27~0.89),P=0.02］.Conclusion:The efficacy and safety of oral Chinese medicine for stable angina pectoris are comparatively good,which is worthy of clinical promotion.

查看全文查看/发表评论下载PDF阅读器